Status:
UNKNOWN
Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
Lead Sponsor:
University of Göttingen
Collaborating Sponsors:
German High-Grade Non-Hodgkin's Lymphoma Study Group
Nordic Lymphoma Group
Conditions:
Peripheral T Cell Lymphoma, Unspecified
Angioimmunoblastic Lymphadenopathy
Eligibility:
All Genders
61-80 years
Phase:
PHASE3
Brief Summary
Peripheral T cell lymphomas comprise 10-15% of all malignant lymphomas. The prognosis is significantly worse than that of aggressive B cell lymphomas. The prospects of elderly patients are especially ...
Eligibility Criteria
Inclusion
- all risk groups of peripheral T cell lymphoma
- performance status ECOG 0-2
- written consent
- measurable disease
Exclusion
- stage I N without bulky disease
- already initiated treatment
- serious accompanying disorder or impaired organ function
- bone marrow involvement \>25%
- HIV positivity
- leukemic manifestation of lymphoma
- simultaneous participation in another trial
- platelets \< 100 000/ mm, leukocytes \< 2500 /mm
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2014
Estimated Enrollment :
274 Patients enrolled
Trial Details
Trial ID
NCT00725231
Start Date
February 1 2008
End Date
March 1 2014
Last Update
May 7 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Göttingen
Göttingen, Lower Saxony, Germany, 37099